Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. | ClinicLens

The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of a cohort of patients with ovarian cancer (OC) wi

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.